Future directions in cardiovascular risk reduction emphasize biomarker-driven prediction, genetic and precision medicine

The gap

Evidence profile

Sourced from the recommendations and future work of the source papers, classified as general, spanning 3 journals.

Supporting evidence — 4 representative gaps

• LDL receptor-independent mechanisms of proprotein convertase subtilisin/kexin type 9 in cardiovascular pathophysiology (2026) · Frontiers in Cardiovascular Medicine · doi

  lowering, accumulating Despite the successful clinical translation of PCSK9-ITs for LDL-C that PCSK9 functions as a pleiotropic regulator of cardiovascular pathophysiology through multiple LDLR-independent mechanisms. These observations open several important avenues for future research and therapeutic development. indicates evidence First, dissecting pathway-specific inhibition remains a priority. Current monoclonal antibodies primarily block the interaction between PCSK9 and LDLR, while leaving the CHRD intact. As the CHRD mediates key inflammatory and immune effects through receptors such as CAP1, CD36, and MHC-I, next- generation inhibitors capable of neutralizing these non-canonical interactions may better address residual inflammatory and thrombotic risk. Second, patient stratification based on non-lipid risk profiles warrants further investigation. Clinical and imaging data suggest that individuals with elevated inflammatory burden, enhanced platelet reactivity, high Lp(a), or early valvular calcification may derive disproportionate benefit from PCSK9-ITs beyond LDL-C reduction. Biomarker-guided strategies could therefore refine patient selection and optimize therapeutic yield. Third, long-term safety of profound PCSK9 suppression requires careful evaluation. Preclinical data indicating metabolic and myocardial consequences of complete PCSK9 deficiency raises important considerations for permanent gene-editing approaches. Future studies should distinguish between partial, reversible in relation to myocardial metabolism and heart failure phenotypes. lifelong ablation, particularly inhibition and Fourth, expanding indications beyond thrombosis, myocardial atherosclerosis represents a promising direction. The involvement of PCSK9 in suggests therapeutic potential in acute coronary syndromes, heart failure remodeling, and valvular heart disease—areas where effective disease-modifying pharmacotherapies remain limited. and CAVD injury Finally, integration of novel therapeutic platforms, including inhibitors, vaccines, and gene-editing oral small-molecule tailor technologies, offers unprecedented opportunities specificity of PCSK9 the depth, duration, inhibition. Comparative these assessing studies modalities differentially modulate LDLR-dependent and LDLR- independent pathways will be essential for defining their optimal clinical roles. tissue how and to

  generalrecommendations
  Keywords: pcsk ldlr therapeutic clinical inhibition inflammatory myocardial heart independent important future speci chrd inhibitors risk
• Assessing residual cardiovascular risk and vulnerable plaques via non-traditional lipids: From biomarkers to novel targets for precision therapy (2026) · World Journal of Cardiology · doi

  Establishing validated thresholds and treatment targets Prospective cohort studies are needed to validate assay- and population-specific risk thresholds, whereas randomized controlled trials are required to determine whether targeted modification of these parameters improves cardiovascular outcomes[11]. This is 21 / 49 particularly important because residual cardiovascular risk may persist despite conventional lipid-lowering strategies[83]. Non-traditional lipid markers such as Lp(a), sdLDL-C, non-HDL-C and RC have been found to be independently linked with a higher risk of cardiovascular events[64,92]. Considering the importance of individual genetic backgrounds, such as Lp(a) and ApoE genotypes, as well as metabolic profiles, future studies should explore how these factors can support more individualized cardiovascular risk assessment and lipid management[93,94]. Moreover, standardization of laboratory assays, harmonization of measurement units, and establishment of population- and assay-specific reference intervals are prerequisites for the broader clinical implementation of non-traditional lipid biomarkers.

  generalfuture work
  Keywords: risk cardiovascular lipid thresholds assay population specific traditional establishing validated treatment targets prospective cohort needed
• Lipoprotein(a) in Personalized Cardiovascular Prevention: Risk Stratification, Coronary Artery Calcium, and Emerging Lp(a)-Lowering Therapies (2026) · Journal of Clinical Medicine · doi

  The central question moving forward is not whether Lp(a) is causal, as this has been firmly established, but whether targeted reduction improves clinical outcomes. Results https://doi.org/10.3390/jcm15176640 J. Clin. Med. 2026, 15, 6640 15 of 17 from ongoing phase 3 trials are expected to clarify this question and will likely determine the future role of Lp(a)-directed therapies in routine practice. In the interim, the priority for clinicians is clear: identify patients with elevated Lp(a) and incorporate this information into risk stratification and management decisions. Given the development of several highly effective Lp(a)-lowering agents, early identification may become increasingly relevant if ongoing outcome trials demonstrate clinical benefit, and therapies subsequently receive regulatory approval. As the field transitions from risk recognition to targeted intervention, Lp(a) may increasingly become a key component of precision cardiovascular prevention, bridging genetic risk, imaging, and individualized therapy. Author Contributions: Conceptualization, A.B.S. and G.V.S.; methodology, A.B.S. and G.V.S.; in- vestigation, A.B.S. and G.V.S.; resources, I.K.R.P.; data curation, A.B.S.; writing—original draft preparation, A.B.S., S.M., I.K.R.P. and G.V.S.; writing—review and editing, A.B.S., S.M., I.K.R.P., A.V. and G.V.S.; visualization, S.M., I.K.R.P. and A.V.; validation, A.V.; supervision, A.V. and G.V.S.; project administration, A.V. and G.V.S. All authors have read and agreed to the published version of the manuscript. Funding: This research received no external funding. Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: No new data was created or analyzed in this study. Data sharing is not applicable to this article. Acknowledgments: The authors would like to thank the Cleveland Clinic Graphics Department for their assistance in preparing the figures and graphical illustrations used in this manuscript. During the preparation of this manuscript, the authors used OpenAI ChatGPT (GPT-5.5) to assist with language editing, improving clarity, manuscript organization, and formatting. The AI-generated output was carefully reviewed, verified, and substantially edited by the authors. All scientific content, literature interpretation, analyses, conclusions, and final editorial decisions were made by the authors, who take full responsibility for the content of this publication. Conflicts of Interest: A.B.S., S.M., I.K.R.P., and A.V. declare no conflicts of interest. G.V.S. has served as a speaker/consultant for MannKind Pharmacy and as a speaker for Bristol-Myers Squibb. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

  generalfuture work
  Keywords: authors manuscript risk writing statement applicable question whether targeted clinical ongoing trials role therapies decisions
• Residual atherosclerotic cardiovascular disease risk in statin-treated patients: mechanisms, therapeutic strategies, and future directions—a scoping review (2026) · Frontiers in Cardiovascular Medicine · doi

  Future directions in cardiovascular risk reduction emphasize biomarker-driven prediction, genetic and precision medicine, rational combination therapy, and careful evaluation of long- term safety and efficacy. These strategies aim to personalize care, expand therapeutic options, and ensure durable outcomes. A summary of emerging strategies and remaining challenges for addressing residual ASCVD risk is presented in Table 3. 5.1 Biomarker-driven risk prediction that

  generalfuture work
  Keywords: risk biomarker driven prediction strategies future directions cardiovascular reduction emphasize genetic precision medicine rational combination

Questions about this gap